Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01895543 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 411
- Enrollment target
NCT01895543 is a Phase 3 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 411 participants.
The verdict
NCT01895543, a Phase 3 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 411 participants
- Enrollment target
Study Summary
Safety and Tolerability Extension Trial for Patients with Chronic Idiopathic Constipation (CIC)
Interventions
- DRUG Elobixibat 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 411 participants |
| Start Date | 2013-09 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01895543
The ClinicalTrials.gov registry entry for NCT01895543 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 411 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Elobixibat 10 mg is the first listed.
NCT01895543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01895543 about?
NCT01895543 is a clinical study titled "Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation". Safety and Tolerability Extension Trial for Patients with Chronic Idiopathic Constipation (CIC)
What is the current status of trial NCT01895543?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 411 participants. The study started on 2013-09. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01895543?
The interventions under investigation include: Elobixibat 10 mg (DRUG).
Who is sponsoring clinical trial NCT01895543?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.